

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CSPC PHARMACEUTICAL GROUP LIMITED**  
**石藥集團有限公司**  
(Incorporated in Hong Kong with limited liability)  
(Stock Code: 1093)

## VOLUNTARY ANNOUNCEMENT

### SYH2085 TABLETS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the SYH2085 tablets (the “**Product**”) developed by the Group have obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is a Class 1 new chemical drug independently developed by the Group. It is a novel oral small-molecule candidate that inhibits the endonuclease activity of the influenza virus RNA polymerase acidic (PA) protein. The indication for this clinical trial approval is for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 years and older. Pre-clinical studies indicated that the Product exhibited clear, broad-spectrum and potent inhibitory activity against both influenza A and B viruses, effectively reducing viral load and influenza-like symptoms in animal models, while demonstrating favourable pharmacokinetic properties and safety profile.

The Product is expected to become an effective treatment for influenza, possessing a promising clinical development value and further enriching the Group’s pipeline in the therapeutic area of anti-infectives.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dong Chen**  
*Chairman*

Hong Kong, 19 December 2025

*As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong, as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.*